OncoMatch/Clinical Trials/NCT07179679
A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors
Is NCT07179679 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies TQB2934 for multiple myeloma.
Treatment: TQB2934 — TQB2934 is an anti-Cluster of Differentiation 3 (CD3) (Early T Cell Marker)×B cell maturation antigen (BCMA) double-specific antibody，and the isoform is IgG1(Native Immunoglobulin G1), which at one end binds to the CD3 receptor on the surface of T cells ,and the other end binds to BCMA(B cell maturation antigen) to recruit T cells around BCMA-positive cells, which can activate T cells .Active T cells release granzyme and perforin to kill BCMA-positive target cells. TQB2934 for injection (subcutaneous injection) is intended for the treatment of patients with multiple myeloma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: proteasome inhibitor
at least one proteasome inhibitor (PI)...are refractory
Must have received: immunomodulator
at least one...immunomodulator (IMiD)...are refractory
Must have received: CD38 monoclonal antibody
at least one...Cluster of Differentiation 38 (CD38) monoclonal antibody are refractory
Cannot have received: allogeneic hematopoietic stem cell transplantation
Exception: within 1 year before the first medication
Have received allogeneic hematopoietic stem cell transplantation within 1 year before the first medication
Cannot have received: autologous hematopoietic stem cell transplantation
Exception: within 12 weeks before the first medication
have received autologous hematopoietic stem cell transplantation (ASCT) within 12 weeks before the first medication
Cannot have received: CD3×BCMA dual antibody therapy
Have received CD3×BCMA dual anti-anti-treatment in the past
Cannot have received: glucocorticoid (dexamethasone)
Exception: cumulative dose >160 mg or equivalent within 4 weeks before the first medication
Cumulative treatment of dexamethasone >160 mg or equivalent dose of other glucocorticoids within 4 weeks before the first medication
Cannot have received: targeted therapy
Exception: within 3 weeks before the first medication
received targeted therapy, cytotoxic drugs or any antibody therapy within 3 weeks before the first medication
Cannot have received: cytotoxic chemotherapy
Exception: within 3 weeks before the first medication
received targeted therapy, cytotoxic drugs or any antibody therapy within 3 weeks before the first medication
Cannot have received: antibody therapy
Exception: within 3 weeks before the first medication
received targeted therapy, cytotoxic drugs or any antibody therapy within 3 weeks before the first medication
Cannot have received: proteasome inhibitor
Exception: within 2 weeks before the first medication
received proteasome inhibitor therapy or radiotherapy within 2 weeks before the first medication
Cannot have received: radiation therapy
Exception: within 2 weeks before the first medication
received proteasome inhibitor therapy or radiotherapy within 2 weeks before the first medication
Cannot have received: immunomodulator
Exception: within 1 week before the first medication
received immunomodulatory therapy within 1 week before the first medication
Cannot have received: Chinese patent medicine with anti-tumor indications
Exception: within 2 weeks before the first medication
received Chinese patent medicine treatments within 2 weeks before the first medication have received National Medical Products Administration (NMPA) -approved drug instructions that clearly have anti-tumor indications
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07179679 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior allogeneic hematopoietic stem cell transplantation, autologous hematopoietic stem cell transplantation, CD3×BCMA dual antibody therapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages